Molecular hydrogen as a pleiotropic agent: a 2026 review of the clinical evidence

Molecular hydrogen (H₂) was long dismissed as biologically inert. Two decades and more than 2,000 papers later, a new Frontiers in Pharmacology review takes stock of H₂ as a 'pleiotropic' agent — one small molecule reported to touch oxidative stress, inflammation, and mitochondrial function across many conditions at once. Its verdict is measured: mechanistically coherent, directionally positive in small trials, and not yet proven where it counts most.

Why hydrogen can reach mitochondria

H₂ is the smallest molecule in biology. It diffuses freely across membranes — into the nucleus, into mitochondria — without transporters or pharmacological help. There it selectively neutralizes the most damaging reactive oxygen species (hydroxyl radicals) while leaving signaling ROS largely intact, a selectivity most antioxidants cannot claim.

What the human evidence shows

Across the review's synthesis: multiple small RCTs support antioxidant and anti-inflammatory effects; exercise studies and meta-analyses (19 studies, 402 participants in 2023; 27 publications, 597 participants in 2024) consistently find reduced perceived exertion and blood lactate, with a small gain in lower-limb explosive power — but no universal improvement in VO₂max, endurance, or strength. In neurology, preliminary trials in Parkinson's and Alzheimer's are inconclusive, with a 179-patient Parkinson's RCT null and a 73-patient cognition RCT null at one year. A Phase 3 post-COVID trial (n=700) is pending.

The delivery problem

Hydrogen-rich water, inhaled gas, and IV hydrogen saline deliver very different doses to tissues, and studies vary widely in concentration and duration — the review's chief methodological complaint. Inhalation offers systemic reach within a single session; oral routes are convenient but dilute. Cross-study comparison remains difficult until protocols standardize.

The honest limits

Most human trials are small, short, and heterogeneous. The review positions H₂ as a candidate adjunct — complementing, not replacing, conventional care — and calls for larger, standardized, longer RCTs. A measurable mitochondrial or biomarker effect is not the same as a patient feeling or functioning better; the review keeps that distinction front and center.

Where the evidence stands

• Established: H2 diffuses into mitochondria and selectively scavenges hydroxyl radicals; multiple RCTs show antioxidant/anti-inflammatory biomarker effects.
• Preliminary: Anti-fatigue effects (perceived exertion, lactate) are supported by two meta-analyses; mitochondrial-disease data rest on one open-label study (n=41). Post-COVID Phase 3 (n=700) is pending.
• Contested: Large trials are inconsistent: Parkinson's RCT (n=179) null; cognition RCT (n=73) null at 1 year; cardiac-arrest data mixed and underpowered.
• Absent: No long-term, adequately powered trial establishes a clinical outcome benefit for any wellness indication.